ReviewTranslational neurodegeneration2017
Nicotine from cigarette smoking and diet and Parkinson disease: a review.
Review in Translational neurodegeneration, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.Journal of neural transmission (Vienna, Austria : 1996) · 2018Pooled it
- The central cholinergic system as a therapeutic target in Parkinson's disease.Journal of Parkinson's disease · 2026Review
- Life's Essential 8 and Parkinson's Disease Risk: A Cross-Sectional Study Based on NHANES Data (2005-2018).Revista de neurologia · 2025Article
- The Role of α7-Nicotinic Acetylcholine Receptors in the Pathophysiology and Treatment of Parkinson's Disease.International journal of molecular sciences · 2025Review
- The Polygenic Risk Score for Parkinson's Disease Is Associated with Becoming a Medical Doctor or Dentist.Genes · 2025Article
- Modifiable risk factors associated with the risk of developing Parkinson's disease: a critical review.Arquivos de neuro-psiquiatria · 2025Review
- Systemically circulating 17β-estradiol enhances the neuroprotective effect of the smoking cessation drug cytisine in female parkinsonian mice.NPJ Parkinson's disease · 2025Article
- Significance of nicotine and nicotinic acetylcholine receptors in Parkinson's disease.Frontiers in aging neuroscience · 2025Review
- Autophagy and UPS pathway contribute to nicotine-induced protection effect in Parkinson's disease.Experimental brain research · 2024Article
- Smoking-diseases correlation database: comprehensive analysis of the correlation between smoking and 422 diseases based on NHANES 2013-2018.Frontiers in public health · 2024Article
- Association between the serum cotinine and trabecular bone score in the adult population: A cross-sectional study.Tobacco induced diseases · 2024Article
- The potential of natural products to inhibit abnormal aggregation of α-Synuclein in the treatment of Parkinson's disease.Frontiers in pharmacology · 2024Review
- Molecular Variability in Levodopa Absorption and Clinical Implications for the Management of Parkinson's Disease.Journal of Parkinson's disease · 2024Review
- Exploratory analysis on the association of dietary live microbe and non-dietary prebiotic/probiotic intake with serum cotinine levels in the general adult population.Frontiers in nutrition · 2024Article
- Potential Therapeutic Approach using Aromatic l-amino Acid Decarboxylase and Glial-derived Neurotrophic Factor Therapy Targeting Putamen in Parkinson's Disease.Current gene therapy · 2024Review
- Linking environmental risk factors with epigenetic mechanisms in Parkinson's disease.NPJ Parkinson's disease · 2023Review
- Melatonin and Health: Insights of Melatonin Action, Biological Functions, and Associated Disorders.Cellular and molecular neurobiology · 2023Review
- The influence of environmental risk factors in the development of ALS in the Mediterranean Island of Cyprus.Frontiers in neurology · 2023Article
- Parkinson's Disease Case Ascertainment in the Sister Study: A Cohort for Environmental Health Research.Journal of Parkinson's disease · 2023Article
- Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Evidence from epidemiological studies suggest a relationship between cigarette smoking and low risk of Parkinson disease (PD). As a major component of tobacco smoke, nicotine has been proposed to be a substance for preventing against PD risk, with a key role in regulating striatal activity and behaviors mediated through the dopaminergic system. Animal studies also showed that nicotine could modulate dopamine transmission and reduce levodopa-induced dyskinesias. However, previous clinical trials yield controversial results regarding nicotine treatment. In this review, we updated epidemiological, preclinical and clinical data, and studies on nicotine from diet. We also reviewed interactions between genetic factors and cigarette smoking. As a small amount of nicotine can saturate a substantial portion of nicotine receptors in the brain, nicotine from other sources, such as diet, could be a promising therapeutic substance for protection against PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.